HUE039516T2 - Eljárás prokarióta fenilalanin-liáz variánsok tisztítására - Google Patents

Eljárás prokarióta fenilalanin-liáz variánsok tisztítására

Info

Publication number
HUE039516T2
HUE039516T2 HUE15202466A HUE15202466A HUE039516T2 HU E039516 T2 HUE039516 T2 HU E039516T2 HU E15202466 A HUE15202466 A HU E15202466A HU E15202466 A HUE15202466 A HU E15202466A HU E039516 T2 HUE039516 T2 HU E039516T2
Authority
HU
Hungary
Prior art keywords
phenylalanine ammonia
lyase variants
prokaryotic phenylalanine
purifying
purifying prokaryotic
Prior art date
Application number
HUE15202466A
Other languages
English (en)
Inventor
Emil D Kakkis
Michel Claude Vellard
Daniel J Wendt
Mubarack Muthalif
Augustus O Okhamafe
Sean M Bell
G Nick Zecherle
Kris Antonsen
Yanhong Zhang
Kieu Y Ly
Paul A Fitzpatrick
Original Assignee
Biomarin Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomarin Pharm Inc filed Critical Biomarin Pharm Inc
Publication of HUE039516T2 publication Critical patent/HUE039516T2/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88Lyases (4.)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51Lyases (4)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y403/00Carbon-nitrogen lyases (4.3)
    • C12Y403/01Ammonia-lyases (4.3.1)
    • C12Y403/01024Phenylalanine ammonia-lyase (4.3.1.24)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14Extraction; Separation; Purification

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
HUE15202466A 2010-02-04 2011-02-03 Eljárás prokarióta fenilalanin-liáz variánsok tisztítására HUE039516T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30147810P 2010-02-04 2010-02-04

Publications (1)

Publication Number Publication Date
HUE039516T2 true HUE039516T2 (hu) 2019-01-28

Family

ID=44356065

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE15202466A HUE039516T2 (hu) 2010-02-04 2011-02-03 Eljárás prokarióta fenilalanin-liáz variánsok tisztítására

Country Status (18)

Country Link
US (4) US20130039898A1 (hu)
EP (4) EP2531209B1 (hu)
JP (1) JP5828844B2 (hu)
CN (2) CN106834261B (hu)
AU (1) AU2011212929B2 (hu)
CA (1) CA2782444C (hu)
CY (1) CY1120768T1 (hu)
DK (1) DK3025728T3 (hu)
ES (2) ES2690542T3 (hu)
HK (1) HK1225299B (hu)
HR (1) HRP20181602T1 (hu)
HU (1) HUE039516T2 (hu)
IL (2) IL221099B (hu)
LT (1) LT3025728T (hu)
PL (1) PL3025728T3 (hu)
PT (1) PT3025728T (hu)
SI (1) SI3025728T1 (hu)
WO (1) WO2011097335A2 (hu)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0319601D0 (en) 2003-08-20 2003-09-24 Sandoz Ag Production process
WO2010014225A2 (en) 2008-07-30 2010-02-04 Biomarin Pharmaceutical Inc. Assays for detection of phenylalanine ammonia-lyase and antibodies to phenylalanine ammonia-lyase
ES2690542T3 (es) 2010-02-04 2018-11-21 Biomarin Pharmaceutical Inc. Método para purificar variantes de fenilalanina amoníaco-liasa procariotas
HUE055899T2 (hu) 2013-04-18 2022-01-28 Codexis Inc Átszerkesztett fenilalanin-ammónia-liáz polipeptidek
DK3145536T3 (da) 2014-04-16 2022-01-03 Codexis Inc Modificeret tyrosinammoniaklyase
TWI743023B (zh) * 2014-05-21 2021-10-21 日商Km生物醫藥股份有限公司 基質金屬蛋白酶 7(mmp-7)聚集體之單體化方法
HUE062016T2 (hu) 2014-12-22 2023-09-28 Codexis Inc Humán alfa-galaktozidáz variánsok
AU2016206208A1 (en) 2015-01-09 2017-08-10 Mcmaster University Allosteric activators for treatment of phenylketonuria
CN106636048A (zh) * 2016-12-14 2017-05-10 江南大学 一株酶活提高的苯丙氨酸脱氨酶突变体
EP3579867A4 (en) 2017-02-13 2021-03-10 Codexis, Inc. MANIPULATED PHENYLALANINE AMMONIA LYASE POLYPEPTIDES
CN108424897B (zh) * 2018-03-13 2020-08-14 广州铭康生物工程有限公司 一种rhTNK-tPA细胞收获液的纯化方法
CN108315338A (zh) * 2018-04-18 2018-07-24 山东省果树研究所 一种石榴苯丙氨酸解氨酶pal及其表达基因与应用
CA3102968A1 (en) 2018-06-12 2019-12-19 Codexis, Inc. Engineered tyrosine ammonia lyase
CA3122524A1 (en) 2018-12-14 2020-06-18 Codexis, Inc. Engineered tyrosine ammonia lyase
EA202191735A1 (ru) 2018-12-20 2021-11-24 Кодексис, Инк. Варианты альфа-галактозидазы человека
KR20220106738A (ko) 2019-08-30 2022-07-29 코덱시스, 인코포레이티드 조작된 리파제 변이체
AU2020408066A1 (en) 2019-12-20 2022-06-30 Codexis, Inc. Engineered acid alpha-glucosidase variants
WO2021168060A1 (en) * 2020-02-19 2021-08-26 Trustees Of Tufts College Methods for engineering amino acid ammonia lyase enzymes and enzymes thereby obtained
JP2023539634A (ja) 2020-08-28 2023-09-15 コデクシス, インコーポレイテッド 操作されたアミラーゼバリアント
BR112023003606A2 (pt) 2020-08-28 2023-03-28 Codexis Inc Protease recombinante, composição, sequência polinucleotídica recombinante, vetor de expressão, célula hospedeira, métodos para produzir uma protease recombinante e para tratar e/ou prevenir os sintomas de insuficiência pancreática, e, uso
CN112662606A (zh) * 2021-01-06 2021-04-16 中国科学院分子植物科学卓越创新中心 用于治疗苯丙酮尿症的工程益生菌
EP4341394A1 (en) 2021-05-19 2024-03-27 BioMarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating adolescent subjects
WO2024032012A1 (zh) * 2022-08-10 2024-02-15 百葵锐(深圳)生物科技有限公司 苯丙氨酸解氨酶突变体及其应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4252822A (en) 1979-12-26 1981-02-24 Children's Hospital Medical Center Method for treating phenylketonuria
US4562151A (en) 1983-09-06 1985-12-31 Monsanto Company Stabilization of L-phenylalanine ammonia-lyase enzyme
EP0167411B1 (en) 1984-07-05 1991-01-09 Mitsubishi Kasei Corporation Microbiological preparation of l-phenylalanine
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US6893625B1 (en) * 1986-10-27 2005-05-17 Royalty Pharma Finance Trust Chimeric antibody with specificity to human B cell surface antigen
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US5766897A (en) 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US5466781A (en) * 1991-05-24 1995-11-14 Chiron Therapeutics Process for purifying bacterially produced M-CSF
ES2184756T3 (es) 1992-11-19 2003-04-16 Anticancer Inc Uso de metioninasa como agente antitumoral en quimioterapia antimetionina.
ES2287926T3 (es) 1992-12-04 2007-12-16 Me Medical Enzymes Ag Glutaminasa manipulada geneticamente y su uso en terapia.
DK75593D0 (hu) 1993-06-25 1993-06-25 Novo Nordisk As
CA2230492C (en) 1995-09-21 2009-05-26 Genentech, Inc. Human growth hormone variants
CU22585A1 (es) 1995-11-17 1999-11-03 Centro Inmunologia Molecular Anticuerpos monoclonales antiidiótipos (ab2) de tipo igg con alta conectividad idiotípica y composiciones farmacéuticas que los contienen. su uso como inmunoreguladores de la respuesta inmune.
US6548644B1 (en) 1997-03-10 2003-04-15 Immunex Corporation Site protected protein modification
US6183738B1 (en) 1997-05-12 2001-02-06 Phoenix Pharamacologics, Inc. Modified arginine deiminase
US5981239A (en) 1997-09-24 1999-11-09 Great Lakes Chemical Corp. Synthesis of optically active phenylalanine analogs using Rhodotorula graminis
US6451986B1 (en) 1998-06-22 2002-09-17 Immunex Corporation Site specific protein modification
US6461849B1 (en) 1998-10-13 2002-10-08 Novozymes, A/S Modified polypeptide
US6686164B1 (en) 1998-10-30 2004-02-03 Novozymes A/S Low allergenic protein variants
US6395299B1 (en) 1999-02-12 2002-05-28 Biostream, Inc. Matrices for drug delivery and methods for making and using the same
US6596849B1 (en) 1999-05-28 2003-07-22 Academia Sinica Monoclonal-antibody for analysis and clearance of polyethylene glycol and polyethylene glycol-modified molecules
US6586398B1 (en) 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
US6939541B2 (en) 2000-04-14 2005-09-06 University Of South Carolina Cloning, overexpression and therapeutic use of bioactive histidine ammonia lyase
US6967097B2 (en) 2000-07-24 2005-11-22 Pcbu Services, Inc. Phenylalainine ammonia lyase polypeptide and polynucleotide sequences and methods of obtaining and using same
WO2002094853A2 (en) 2001-05-21 2002-11-28 Nektar Therapeutics Al, Corporation Antibodies specific for poly(ethylene glycol)
US6939941B2 (en) 2001-09-12 2005-09-06 Toray Fine Chemicals Co., Ltd. Preparation of polysulfide compositions
EP1476563B1 (en) 2002-02-26 2008-09-17 E.I. Du Pont De Nemours And Company Method for the recombination of genetic elements
WO2004024125A1 (en) * 2002-09-16 2004-03-25 Wyeth Delayed release formulations for oral administration of a polypeptide therapeutic agent and methods of using same
US20080124275A1 (en) 2002-11-14 2008-05-29 The Scripps Research Institute Crystalline Form of Fatty Acid Amide Hydrolase (Faah)
US7141544B2 (en) * 2003-10-10 2006-11-28 Baxter International, Inc. Stabilization of pharmaceutical protein formulations with small peptides
US8114958B2 (en) * 2004-02-11 2012-02-14 Amylin Pharmaceuticals, Inc. Amylin family peptides
AU2005286763A1 (en) 2004-09-17 2006-03-30 Biomarin Pharmaceutical, Inc. Variants and chemically-modified variants of phenylalanine ammonia-lyase
EP1869174B1 (en) 2005-03-10 2015-02-18 BASF Enzymes LLC Lyase enzymes, nucleic acids encoding them and methods for making and using them
TW200806317A (en) * 2006-03-20 2008-02-01 Wyeth Corp Methods for reducing protein aggregation
US7534595B2 (en) * 2006-06-12 2009-05-19 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US7531341B1 (en) 2006-06-12 2009-05-12 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
WO2008069958A2 (en) 2006-12-01 2008-06-12 The Salk Institute For Biological Studies Substrate switched ammonia lyases and mutases
US7560263B2 (en) 2007-08-17 2009-07-14 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof
WO2010014225A2 (en) * 2008-07-30 2010-02-04 Biomarin Pharmaceutical Inc. Assays for detection of phenylalanine ammonia-lyase and antibodies to phenylalanine ammonia-lyase
ES2690542T3 (es) 2010-02-04 2018-11-21 Biomarin Pharmaceutical Inc. Método para purificar variantes de fenilalanina amoníaco-liasa procariotas

Also Published As

Publication number Publication date
JP5828844B2 (ja) 2015-12-09
EP2531209A4 (en) 2013-07-03
JP2013518893A (ja) 2013-05-23
US20240035013A1 (en) 2024-02-01
ES2582459T3 (es) 2016-09-13
EP2531209A2 (en) 2012-12-12
US20190345475A1 (en) 2019-11-14
US11505790B2 (en) 2022-11-22
IL221099B (en) 2018-02-28
PT3025728T (pt) 2018-11-05
EP4062928A3 (en) 2022-11-30
AU2011212929B2 (en) 2016-10-27
CN106834261B (zh) 2022-02-18
WO2011097335A2 (en) 2011-08-11
LT3025728T (lt) 2018-10-25
CA2782444C (en) 2018-10-23
WO2011097335A3 (en) 2011-10-20
EP4062928A2 (en) 2022-09-28
EP3025728A1 (en) 2016-06-01
HRP20181602T1 (hr) 2018-11-30
CN106834261A (zh) 2017-06-13
AU2011212929A1 (en) 2012-06-21
US10221408B2 (en) 2019-03-05
IL257437B (en) 2019-06-30
EP3479842A2 (en) 2019-05-08
US20130039898A1 (en) 2013-02-14
CN102753566A (zh) 2012-10-24
US20160362675A1 (en) 2016-12-15
CA2782444A1 (en) 2011-08-11
IL257437A (en) 2018-04-30
DK3025728T3 (en) 2018-10-29
SI3025728T1 (sl) 2018-11-30
EP2531209B1 (en) 2016-04-20
EP3025728B1 (en) 2018-08-08
ES2690542T3 (es) 2018-11-21
HK1225299B (zh) 2017-09-08
PL3025728T3 (pl) 2018-12-31
EP3479842A3 (en) 2019-07-17
CY1120768T1 (el) 2019-12-11

Similar Documents

Publication Publication Date Title
HRP20181602T1 (hr) Postupak pročišćavanja prokariotskih varijanti i fenilalanin-amonijak-lijaze
HRP20181468T1 (hr) Postupak za dekodiranje video zapisa korištenjem spajanja blokova
PL2608541T3 (pl) Sposób dekodowania intra-predykcji
ZA201502761B (en) Method for decoding a video
HK1176946A1 (zh) 純化免疫球蛋白溶液的方法
IL207429A0 (en) A method of purifying a peptide
EP2634142A4 (en) PROCESS FOR THE PURIFICATION OF CHLOROSILANES
IL243248A0 (en) Purification method
GB2507704B (en) Tightening system
PT2598516E (pt) Processo de purificação de proteínas
EP2727930A4 (en) PROCESS FOR CLEANING PROTEINS
HK1215003A1 (zh) 鈣的除去方法
EP2684369A4 (en) METHOD FOR DECODING VIDEO DATA
ZA201302330B (en) Method for purifying water
EP2743259B8 (en) Method for purifying (s)-oxiracetam
ZA201300320B (en) Purification process
EP2743258A4 (en) PROCESS FOR PURIFYING LEVO-OXIRACETAM
GB201004372D0 (en) Compounds for purification
EP2454240A4 (en) GLYCINTRANSPORTERHEMMER
EP2762486A4 (en) PROCESS FOR PURIFYING PROTEIN
HK1214960A1 (zh) 用於純化肝素- -硫酸的方法
PL393099A1 (pl) Układ taktowania mikroprocesora